Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells

BACKGROUND: Up to 10 % of primary gastric cancers are characterized by FGFR2 amplification, and fibroblast growth factor receptor (FGFR) inhibitors may represent therapeutic agents for patients with these malignancies. However, long-term benefits of the treatment might be limited owing to the occurr...

Descripción completa

Detalles Bibliográficos
Autores principales: Grygielewicz, Paulina, Dymek, Barbara, Bujak, Anna, Gunerka, Pawel, Stanczak, Aleksandra, Lamparska-Przybysz, Monika, Wieczorek, Maciej, Dzwonek, Karolina, Zdzalik, Daria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688307/
https://www.ncbi.nlm.nih.gov/pubmed/25407459
http://dx.doi.org/10.1007/s10120-014-0444-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688307/
https://www.ncbi.nlm.nih.gov/pubmed/25407459
http://dx.doi.org/10.1007/s10120-014-0444-1

Ejemplares similares